Joel David Mayersohn - 19 Sep 2025 Form 4 Insider Report for CITIUS ONCOLOGY, INC. (CTOR)

Role
Director
Signature
/s/Alexander M. Donaldson, by Power of Attorney
Issuer symbol
CTOR
Transactions as of
19 Sep 2025
Transactions value $
$0
Form type
4
Filing time
23 Sep 2025, 16:10:15 UTC
Previous filing
07 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Mayersohn Joel David Director C/O CITIUS ONCOLOGY, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD /s/Alexander M. Donaldson, by Power of Attorney 23 Sep 2025 0001588395
This filing has been restated, see here for the amended filing

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTOR Common Stock Award $0 +300,000 +14.13% $0 321,228 19 Sep 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CTOR Stock Option (Right to Buy) 250,000 19 Sep 2025 Common Stock 250,000 $1.07 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock awards granted on September 19, 2025. The shares will vest in three substantially equal installments on the first, second and third anniversaries of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
F2 These options were granted on December 12, 2024. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the grant date, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.